Literature DB >> 9826376

The (alpha2-->8)-linked polysialic acid capsule and lipooligosaccharide structure both contribute to the ability of serogroup B Neisseria meningitidis to resist the bactericidal activity of normal human serum.

C M Kahler1, L E Martin, G C Shih, M M Rahman, R W Carlson, D S Stephens.   

Abstract

The molecular basis for the resistance of serogroup B Neisseria meningitidis to the bactericidal activity of normal human sera (NHS) was examined with a NHS-resistant, invasive serogroup B meningococcal isolate and genetically and structurally defined capsule-, lipooligosaccharide (LOS)-, and sialylation-altered mutants of the wild-type strain. Expression of the (alpha2-->8)-linked polysialic acid serogroup B capsule was essential for meningococcal resistance to NHS. The very NHS-sensitive phenotype of acapsular mutants (99.9 to 100% killed in 10, 25, and 50% NHS) was not rescued by complete LOS sialylation or changes in LOS structure. However, expression of the capsule was necessary but not sufficient for a fully NHS-resistant phenotype. In an encapsulated background, loss of LOS sialylation by interrupting the alpha2,3 sialyltransferase gene, lst, increased sensitivity to 50% NHS. In contrast, replacement of the lacto-N-neotetraose alpha-chain (Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc) with glucose extensions (GlcN) in a galE mutant resulted in a strain resistant to killing by 50% NHS at all time points. Encapsulated meningococci expressing a Hep2(GlcNAc)-->KDO2-->lipid A LOS without an alpha-chain demonstrated enhanced sensitivity to 50% NHS (98% killed at 30 min) mediated through the antibody-dependent classical complement pathway. Encapsulated LOS mutants expressing truncated Hep2-->KDO2-->lipid A and KDO2-->lipid A structures were also sensitive to 50% NHS (98 to 100% killed at 30 min) but, unlike the wild-type strain and mutants with larger oligosaccharide structures, they were killed by hypogammaglobulinemic sera. These data indicate that encapsulation is essential but that the LOS structure contributes to the ability of serogroup B N. meningitidis to resist the bactericidal activity of NHS.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9826376      PMCID: PMC108752     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  66 in total

1.  The lipooligosaccharide immunotype as a virulence determinant in Neisseria meningitidis.

Authors:  D M Jones; R Borrow; A J Fox; S Gray; K A Cartwright; J T Poolman
Journal:  Microb Pathog       Date:  1992-09       Impact factor: 3.738

2.  Sialic acid of group B Neisseria meningitidis regulates alternative complement pathway activation.

Authors:  G A Jarvis; N A Vedros
Journal:  Infect Immun       Date:  1987-01       Impact factor: 3.441

3.  Intercontinental spread of a genetically distinctive complex of clones of Neisseria meningitidis causing epidemic disease.

Authors:  D A Caugant; L O Frøholm; K Bøvre; E Holten; C E Frasch; L F Mocca; W D Zollinger; R K Selander
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

4.  Identification of a genetic locus involved in the biosynthesis of N-acetyl-D-mannosamine, a precursor of the (alpha 2-->8)-linked polysialic acid capsule of serogroup B Neisseria meningitidis.

Authors:  J S Swartley; D S Stephens
Journal:  J Bacteriol       Date:  1994-03       Impact factor: 3.490

5.  Expression of the L8 lipopolysaccharide determinant increases the sensitivity of Neisseria meningitidis to serum bactericidal activity.

Authors:  E E Moran; B L Brandt; W D Zollinger
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

6.  Lipopolysaccharide heterogeneity and escape mechanisms of Neisseria meningitidis: possible consequences for vaccine development.

Authors:  S Rune Andersen; J Kolberg; E A Høiby; E Namork; D A Caugant; L Oddvar Frøholm; E Jantzen; G Bjune
Journal:  Microb Pathog       Date:  1997-09       Impact factor: 3.738

7.  Functional relationships of the genetic locus encoding the glycosyltransferase enzymes involved in expression of the lacto-N-neotetraose terminal lipopolysaccharide structure in Neisseria meningitidis.

Authors:  W Wakarchuk; A Martin; M P Jennings; E R Moxon; J C Richards
Journal:  J Biol Chem       Date:  1996-08-09       Impact factor: 5.157

8.  Two glycosyltransferase genes, lgtF and rfaK, constitute the lipooligosaccharide ice (inner core extension) biosynthesis operon of Neisseria meningitidis.

Authors:  C M Kahler; R W Carlson; M M Rahman; L E Martin; D S Stephens
Journal:  J Bacteriol       Date:  1996-12       Impact factor: 3.490

9.  Common epitopes of pilin of Neisseria meningitidis.

Authors:  D S Stephens; A M Whitney; G K Schoolnik; W D Zollinger
Journal:  J Infect Dis       Date:  1988-08       Impact factor: 5.226

10.  Inner core biosynthesis of lipooligosaccharide (LOS) in Neisseria meningitidis serogroup B: identification and role in LOS assembly of the alpha1,2 N-acetylglucosamine transferase (RfaK).

Authors:  C M Kahler; R W Carlson; M M Rahman; L E Martin; D S Stephens
Journal:  J Bacteriol       Date:  1996-03       Impact factor: 3.490

View more
  74 in total

1.  Polymorphisms in pilin glycosylation Locus of Neisseria meningitidis expressing class II pili.

Authors:  C M Kahler; L E Martin; Y L Tzeng; Y K Miller; K Sharkey; D S Stephens; J K Davies
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

2.  Characterization and acceptor preference of a soluble meningococcal group C polysialyltransferase.

Authors:  Dwight C Peterson; Gayathri Arakere; Justine Vionnet; Pumtiwitt C McCarthy; Willie F Vann
Journal:  J Bacteriol       Date:  2011-01-28       Impact factor: 3.490

3.  Genetic basis for biosynthesis of the (alpha 1-->4)-linked N-acetyl-D-glucosamine 1-phosphate capsule of Neisseria meningitidis serogroup X.

Authors:  Yih-Ling Tzeng; Corie Noble; David S Stephens
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

Review 4.  A bacterial siren song: intimate interactions between Neisseria and neutrophils.

Authors:  Alison K Criss; H Steven Seifert
Journal:  Nat Rev Microbiol       Date:  2012-01-31       Impact factor: 60.633

5.  Comparison of Phenotypic and Genotypic Approaches to Capsule Typing of Neisseria meningitidis by Use of Invasive and Carriage Isolate Collections.

Authors:  C Hal Jones; Naglaa Mohamed; Eduardo Rojas; Lubomira Andrew; Johanna Hoyos; Julio C Hawkins; Lisa K McNeil; Qin Jiang; Leonard W Mayer; Xin Wang; Rodica Gilca; Philippe De Wals; Louise Pedneault; Joseph Eiden; Kathrin U Jansen; Annaliesa S Anderson
Journal:  J Clin Microbiol       Date:  2015-08-26       Impact factor: 5.948

6.  O-Acetylation of sialic acid on Group B Streptococcus inhibits neutrophil suppression and virulence.

Authors:  Shannon Weiman; Satoshi Uchiyama; Feng-Ying C Lin; Donald Chaffin; Ajit Varki; Victor Nizet; Amanda L Lewis
Journal:  Biochem J       Date:  2010-05-13       Impact factor: 3.857

7.  Distribution of serogroups and genotypes among disease-associated and carried isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway.

Authors:  Siamak P Yazdankhah; Paula Kriz; Georgina Tzanakaki; Jenny Kremastinou; Jitka Kalmusova; Martin Musilek; Torill Alvestad; Keith A Jolley; Daniel J Wilson; Noel D McCarthy; Dominique A Caugant; Martin C J Maiden
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

8.  Cationic antimicrobial peptide resistance in Neisseria meningitidis.

Authors:  Yih-Ling Tzeng; Karita D Ambrose; Susu Zughaier; Xiaoliu Zhou; Yoon K Miller; William M Shafer; David S Stephens
Journal:  J Bacteriol       Date:  2005-08       Impact factor: 3.490

Review 9.  Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis.

Authors:  David S Stephens
Journal:  Vaccine       Date:  2009-05-23       Impact factor: 3.641

10.  Pathogenesis, Therapy, and Prevention of Meningococcal Sepsis.

Authors:  David S. Stephens; Shanta M. Zimmer
Journal:  Curr Infect Dis Rep       Date:  2002-10       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.